Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaResearch in context

Summary: Background: We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role of adjuvant rituximab and translational studies. Methods: Patients with ESFL were randomised to involved field radiotherapy (I...

Descripción completa

Detalles Bibliográficos

Autores principales:	Michael P. MacManus, John F. Seymour, Hennes Tsang, Richard Fisher, Colm Keane, Muhammed B. Sabdia, Soi C. Law, Jay Gunawardana, Karthik Nath, Stephen H. Kazakoff, Mario L. Marques-Piubelli, Daniela E. Duenas, Michael R. Green, Daniel Roos, Peter O'Brien, Andrew McCann, Richard Tsang, Sidney Davis, David Christie, Chan Cheah, Benhur Amanuel, Tara Cochrane, Jason Butler, Anna Johnston, Mohamed Shanavas, Li Li, Claire Vajdic, Robert Kridel, Victoria Shelton, Samantha Hershenfield, Tara Baetz, David Lebrun, Nathalie Johnson, Marianne Brodtkorb, Maja Ludvigsen, Francesco d’Amore, Ella R. Thompson, Piers Blombery, Maher K. Gandhi, Joshua W.D. Tobin
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2024-12-01
Colección:	EBioMedicine
Materias:	Early-stage follicular lymphoma Rituximab Radiotherapy CD8 Neoantigen. randomized clinical trial
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2352396424005048
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!